Reference
Mariotto A, et al. Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. Journal of the National Cancer Institute : 24 Apr 2019. Available from: URL: http://doi.org/10.1093/jnci/djz068
Rights and permissions
About this article
Cite this article
Breast cancer treatment based on Oncotype DX test saves costs. PharmacoEcon Outcomes News 830, 6 (2019). https://doi.org/10.1007/s40274-019-5957-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5957-8